

# Comments on EFSA's scientific draft opinion on acrylamide in food

Janneke Hogervorst  
Dept. of Epidemiology  
Maastricht University  
EFSA public consultation  
Dec 10 2014

# Comments

- Uncertainty in risk assessment:  
major, not moderate  
(page 186)
- Recommendations on research needs  
(page 192)
  - cancer risk
  - neurological disease risk / cognitive development
  - cardiovascular disease risk

# EFSA draft scientific opinion AA in food

Risk characterization based entirely on rodent data

Conclusions:

- Neoplastic effects: MOE indicates concern
- Non-carcinogenic effects: MOE indicates no concern
- Level of uncertainty in risk assessment: **moderate**

Epidemiological data considered inconsistent and biological plausibility unclear > discussed but not used in RA

# Ovarian cancer

2 studies show statistically significant positive association:

- Netherlands Cohort Study (stronger in never-smokers) (Hogervorst 2007)
- Nurses' Health Study (in normal-weight women and for serous ovarian cancer) (Wilson 2010)

## **Meta-analysis Pelucchi, Nov 2014:**

Relative risk never-smokers: 1.39

95% CI: 0.97-2.00

Nurses' Health Study: no association between AA and GA Hb adducts and ovarian cancer risk  
(Xie 2013)

# Hb adducts

Hb adducts: no gold standard for assessing long-term dietary AA exposure

- Large intra-individual variation
- Influence of incidental high exposures
- Expressed per g hemoglobin
- “Low association between the AA-adduct levels and questionnaire data points towards shortcomings of both methods” (Vikström, 2012)

Studies correlating questionnaire data with Hb adduct data should not be called “validation studies” (page 185)

# Endometrial cancer

3 studies show statistically significant positive association:

- Netherlands Cohort Study: only in never-smokers (Hogervorst 2007)
- Nurses' Health Study (Wilson 2010)
- not in draft RA: European Prospective Investigation into Cancer and Nutrition: only in never-smokers and non-users of OC (Obon-Santacana 2014)

**Meta-analysis Pelucchi, Nov 2014:**

Relative risk never-smokers = 1.23

95% CI: 1.00-1.51

NTP 2012: endometrial hyperplasia in rats

# Kidney cancer

1 study shows statistically significant positive association:

- Netherlands Cohort Study (Hogervorst 2008)

3 other out of 5 studies in total show increased risk

## **Meta-analysis Pelucchi 2014:**

Relative risk = 1.20

95% CI: 1.00-1.45

# Biological plausibility cancer

## **Norwegian BraMat cohort**

(Hochstenbach 2012)

Male newborns:

- Pos. correlation cord blood AA-Hb and GA-Hb and **micronuclei**  
0.75 + 0.73 (non-smoking mothers)
- Pos. correlation gene expression **wnt pathway**

## **Taiwanese cross-sectional study**

(Lin 2013)

- Positive association urinary AAMA and **8-OHdG** in non-smoking adolescents

# Biological plausibility cancer (continued)

## **Nurses' Health Study**

(Hogervorst 2013)

- Some associations AA intake and **sex hormones** but no clear picture

## **Netherlands Cohort Study**

(Hogervorst)

- Preliminary data: association between acrylamide intake and endometrial cancer risk modified by SNPs in CYP2E1

# Acrylamide and birth outcomes

## **Prospective mother-child cohort**

(Denmark, UK, Greece, Norway, Spain)

(Pedersen 2012)

**Inverse** association cord blood AA and GA-Hb and:

- Birth weight
- Head circumference

## **Norwegian prospective mother-child cohort**

(Duarte-Salles 2013)

- **Inverse** association AA intake and birth weight
- **Positive** association risk small for gestational age

# Back to EFSA draft RA

## Epidemiology:

- Not consistent (cancer)
- Limited evidence for biological plausibility

But

- ✓ Multiple good quality studies show positive associations
- ✓ Null findings do not negate positive findings
- ✓ Measurement error in AA does not lead to false-positive findings, but false-negatives, (RR in direction of null)

## But....

- ✓ Studies with positive findings seem better suited to study association acrylamide and cancer (should be discussed in EFSA RA)
- ✓ Pelucchi meta-analysis, Nov 2014:  
“A modest association for kidney cancer, and for endometrial and ovarian cancers in never-smokers only, cannot be excluded”
- ✓ Some (limited) human evidence for biological plausibility

Perhaps too early to base risk assessment on, but should **at least be appreciated in assessment of uncertainty**

# Uncertainty

If true, cancer and developmental toxicity risks  
**much higher** than estimate based on rodents

Table 31 draft RA:

+/- as given for uncertainty related to inconsistency  
human studies on cancer should be –

Table 31 draft RA:

how about uncertainty related to developmental  
effects? (2 positive studies on birth weight in  
humans: if true, MOE for dev. tox. is 1)

The uncertainty in EFSA risk assessment  
is not moderate but major

# Research needs

## Epidemiological studies

- Cancer risk: why not in draft RA?
- Birth outcomes
- Biological plausibility/causality, e.g., polymorphisms modifying risk (e.g., CYP2E1)
- Cardiovascular effects (Toker, 2013, see page 108 of EFSA report, oxidative stress)


# Research needs (continued)

- Neurotoxic effects (e.g., dementia, cognitive development): not in draft RA
  - ✓ AA affects both PNS and CNS
  - ✓ Accumulation of AA to cys adducts in CNS
  - ✓ Nerve degeneration
  - ✓ Cumulative
  - ✓ No regeneration of damaged neurons in CNS
  - ✓ Animal models are no good models for human neurotoxicity in terms of cognition, behaviour
  - ✓ Inverse association head circumference
  - ✓ Other researchers recommend research on neurotoxicity: El Sayyad, LoPachin


# Questions?

# Ovarian cancer


- FFQ
- Highest vs lowest category of AA intake
- Corrected for covariables (confounders)




# Ovarian cancer, never-smokers



# Endometrial cancer



# Endometrial cancer, never-smokers



# Kidney cancer

